NCT07140211View on ClinicalTrials.gov

Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

9,200

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

August 31, 2030

Study Completion Date

August 31, 2030

Conditions

Venous Thromboembolism (VTE)Postpartum

Interventions

DRUG

Low-dose low-molecular-weight heparin

"Low-molecular-weight heparin given for 7-10 days after delivery:~* enoxaparin 4000-6000IU o.d.~* nadroparin 3800-5700IU o.d.~* dalteparin 5000-7500IU o.d.~* tinzaparin 4500-7000IU o.d."

All Listed Sponsors

lead

Marc Blondon

OTHER